Shares of Dr Reddy's Laboratories jumped 5.3 per cent on Thursday to Rs 1,217 apiece, making it the top gainer in the Nifty 50 and the BSE 100 indices. By comparison, the Nifty 50 was up 0.53 per cent at 25,289.
Pharma major Dr Reddy's Laboratories (DRL) reported a 14 per cent year-on-year (Y-o-Y) drop in consolidated net profit to Rs 1,210 crore in the December quarter of FY 2025-26 (Q3FY26) on low sales of cancer drug Lenalidomide in the North American market. The firm's revenue from operations grew to Rs 8,727 crore in Q3FY26, a 4.4 per cent Y-o-Y increase from Rs 8,357 crore recorded for the same quarter last year.
Buoyant domestic sales are expected to lift revenues for pharma companies by 8-11 per cent in Q3FY26, even as declining generic Revlimid (cancer drug) sales in the US remain a key drag. Most brokerages forecast a modest 2-4 per cent growth in profit after tax (PAT) for the quarter. Hospitals and diagnostics companies, meanwhile, are likely to post much stronger numbers, with revenues seen growing 20-22 per cent year-on-year (Y-o-Y).
Though some ingredients such as mild odours or silicones might not be actually harmful, others such as sulphates, parabens or formaldehyde releasers can result in skin irritation, hormonal imbalances and skin barrier damage, advises Dr Ameesha Mahajan.
'It's a lifetime opportunity to cook for the most high-profile table of India. It's a matter of honour for me.'
India has been on an FTA-signing spree of late. Since 2021, it has signed eight trade agreements, three of which -- with the UK, Oman and New Zealand -- were finalised in 2025 alone.
Earlier in the day, the ministry of external affairs "strongly advised" Indians to avoid travel to Iran until further notice, amid rising tensions and protests in the Islamic Republic.
'As more patients are prescribed these drugs, intolerance due to gastrointestinal and other side effects will become more visible, leading to higher discontinuation rates.'
The semaglutide patent expiry next year could unleash a wave of generic versions from Indian drugmakers, with prices expected to go lower -- at least 80 per cent.
'After Kohli's hundred at Ranchi, the second and third phases vanished in minutes. Nothing was left unsold.'
Developers are entering one of the busiest construction cycles, with the top four firms planning launches worth Rs 1.13 trillion over the near to medium term, even as execution faces pressure from approval delays, labour shortages, rising costs, and contractor capacity limits across the industry.
The fierce battles of Galwan, Rezang La, Gurung Hill, and Walong taught the PLA a hard lesson: Fighting the Indian Army would never be easy or inexpensive.
Prada's Kolhapuri chappals will debut globally in February across 40 Prada stores and on the brand's e-commerce platform.
The former Australian opener suggested that KKR could benefit from releasing Iyer and attempting to buy him back at a more balanced price point.
The recipe for Indian higher education institutions to succeed in the global markets is excellence in academics, promoting contemporary socially relevant material, and enabling individuals (learners) to realise their full potential, suggests N Ravichandran.
In a measured but scathing attack, Congress MP Priyanka Gandhi Vadra on Monday accused the Bharatiya Janata Party of committing a 'big sin' by creating a controversy over Vande Mataram and claimed that the government pushed for a debate on the national song as the West Bengal assembly polls were approaching.
The Union Cabinet on Wednesday increased Dearness Allowance (DA) and Dearness Relief (DR) by 3 per cent for about 49.19 lakh central government employees and 68.72 lakh pensioners.
'Everybody in America loses because of what India is doing.'
Dr Sulbha Arora, clinical director and fertility specialist at Nova IVF Fertility, explains everything you need to know about egg freezing in India, including the process, the cost and the risks involved.
Pharma major Dr Reddy's Laboratories delivered a muted operational performance in the fourth quarter of financial year 2024-25 (Q4FY25), even as revenue growth remained healthy. Lower gross margin performance and muted domestic growth are key concerns. Most brokerages have a "Sell" or "Reduce" rating as there are uncertainties related to the development of a new product portfolio and the launch timelines.
Equity market investors would track global trends, foreign fund movement and quarterly earnings in a holiday-shortened week ahead, analysts said. Stock exchanges BSE and NSE will conduct a special Muhurat trading session on Tuesday, October 21.
'Nutrition is always higher when you consume fresh food. Whether it's heated, boiled, frozen or microwaved, some nutrient depletion always happens' says Dr Rajeshwari Panda.
Israel Defence Forces carried out air strikes, killing nine people in Gaza, following an alleged violation of the United States-brokered ceasefire deal by Hamas, CNN reported.
US accounts for a large part of revenue for top Indian pharma companies like Gland Pharma (54 percent), Dr Reddy's (53 per cent), and Aurobindo Pharma (48 per cent).
The US Food and Drug Administration's (USFDA)'s new draft guidelines aimed at speeding up and reducing the cost of developing biosimilars - lower-priced, near-replicas of complex biologic medicines - could significantly benefit Indian biotech companies.
Govinda and Chunky Panday are an absolute delight in the fourth episode of Too Much With Kajol and Twinkle.
'They are totally disconnected with farm activities which their families have been involved in for years.'
Prime Minister Narendra Modi on Friday launched a sharp attack on country's first premier Jawaharlal Nehru, claiming he prevented Sardar Vallabhbhai Patel from fully integrating Kashmir into the Indian Union.
Concerns over weakening demand for Indian pharmaceutical (pharma) drugs in the US - their largest export market - have weighed heavily on investor sentiment this year. While the Nifty 50 has gained 6.02 per cent year - to - date (as on September 15), the Nifty Pharma index has declined 5.18 per cent, National Stock Exchange data shows.
'Famine in Gaza is not a failure of logistics or aid. What is to blame is deliberate starvation caused by a brutal war.' 'Any child dying in a war zone is a vote of no confidence against humanity.'
As a protege of Shinzo Abe, Takaichi is expected to scale bilateral ties much higher. Trade and investment shall grow. People-to-people contacts shall be scaled up, points out Dr Rajaram Panda.
22 images that captures glimpses of a most unusual Indian who led the nation for 10 years.
India is home to more than 100 million diabetics, and the demand for anti-diabetic drugs is on the rise -- the Rs 20,611 crore anti-diabetic drug market in India is growing at 9 per cent or so.
'The US reciprocal tariff has added another element of uncertainty and the central bank may prefer to wait and get further clarity.'
Prices for Indian consumers are expected to come down significantly from the current Rs 17,000-Rs 26,000 monthly.
The news that Amazon India has launched diagnostic services in select metro cities in partnership with the unlisted Orange Health Labs has led to a look at the competitive intensity in healthcare services. Listed companies in the space such as Dr Lal Path Labs, Metropolis Health, Thyrocare, Vijaya, and Krsnaa have all seen double-digit stock price corrections over the last 6-9 months.
'New Delhi is not naive about its foreign policy choices.'
Prime Minister Shigeru Ishiba's sudden resignation after only a year in office has thrown Japan into political turmoil, raising doubts about how the country will handle economic and regional challenges, observes Dr Rajaram Panda.
'...it should not delude itself into thinking that India's security or its great-power ambitions will be advanced by those partnerships.'
'Instead, what India should focus on is on riding out the next three-and-a-half years of Trump's presidency with minimal damage to itself.'
'Mrs Gandhi had nothing to do in the day-to-day working of Dr Singh's government.' 'People say Mrs Gandhi's office used to give orders, which is nonsense.'
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances